About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Pfizer Biotech Chief Signs Vow of Silence for $1.7 Million

By Jim Edwards | Apr 28, 2009

Corey Goodman, the guy hired to run Pfizer’s “Bioinnovation Center” in San Francisco, signed an omertà-style vow upon leaving the company: He must never talk about Pfizer again, to anyone, ever, the agreement basically states.

Pfizer, which had too many R&D chiefs following its decision to merge with Wyeth, made Goodman an offer he couldn’t refuse: Leave quietly and you won’t have to pay back a $1.7 million loan.

But to get that $1.7 million, Goodman had to sign the following vow of silence. You’ll note that technically it does allow Goodman to talk about his time at Pfizer — as long as he’s being forced to for legal reasons or as long as he only says nice things about the company.

But as he’s banned from saying anything “true or false” (!) that might cast Pfizer “in a critical or unfavorable light,” his lawyer will simply advise him never to talk about Big Blue again.

Here’s what the parchment says:

Dr. Goodman will not disparage any Pfizer Released Party or any Pfizer Released Party’s goods, services, employees, customers, business relationships, or financial condition. No member of Pfizer’s Executive Leadership Team will disparage Dr. Goodman. For purposes of this Agreement, to “disparage” means to make statements, whether true or false, that cast the subject of the statement in a critical or unfavorable light. Nothing in the foregoing will preclude Dr. Goodman or the other individuals referenced in this paragraph from providing truthful disclosures to an appropriate government agency, arbitrator, or court related to a legally-required filing, a governmental investigation, or a pending matter in controversy.

Neither Dr. Goodman nor anyone acting by, through, under or in concert with him will speak to the press or other news or public media about his employment at Pfizer, the circumstances of his resignation from employment with Pfizer, or this Agreement, other than remarks or responses consistent with the agreed-upon communication described in paragraph 3 of this Agreement. Neither any member of Pfizer’s Executive Leadership Team, nor any member of the Pfizer media relations team or the Pfizer investor relations team, nor anyone acting by, through, under or in concert with such person, will speak to the press or other news or public media about Dr. Goodman’s employment at Pfizer, the circumstances of his resignation from employment with Pfizer, or this Agreement, other than remarks or responses consistent with the agreed-upon communication described in paragraph 3 of this Agreement. Notwithstanding the foregoing, this Agreement may be disclosed as required by applicable securities or other laws, and introduced as evidence in a subsequent proceeding in which either Dr. Goodman or a Released Party alleges a breach of this Agreement, or one of them asserts any claim or commences any legal proceeding against the other.

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • Pfizer's R&D shakeup based on bio-innovation

    FierceMarkets - 265 days 13 hours 47 minutes ago

    How does a pharma giant like Pfizer get entrepreneurial in the biotech field? For Corey Goodman, head of Pfizer's Biotherapeutics & Bioinnovations Center in San Francisco , the answer lies in small teams of scientists who stay with a program as it advances through clinical trials. And Pfizer has decided to take the same approach across its...

  • Pfizer: Making It 'Leaner, Meaner, More Efficient'

    BusinessWeek - 269 days 5 hours 14 minutes ago

    When Pfizer (PFE) CEO Jeffrey B. Kindler first met with Corey Goodman about being the head of the pharmaceutical giant's Biotherapeutics & Bioinnovations Center (BBC) based in San Francisco in the summer of 2007, he handed him a big assignment: Kindler wanted Goodman to develop a new model to do research in a more efficient, more entrepreneurial...

  • Pfizer's biotech leader makes an unexplained exit

    FierceMarkets - 209 days 15 hours 48 minutes ago

    Corey Goodman had been Pfizer#039s go-to guy for biotechnology. But now he#039s out. Goodman was brought in 19 months ago as the senior vice president in charge of Pfizer#039s California biotechnology center, which was designed to spearhead the pharma giant#039s drive into the biotech sphere. In an SEC filing, Pfizer disclosed that...

  • On Pfizer’s missing offer letter…

    Footnoted - 207 days 18 hours 11 minutes ago

    On Tuesday morning, Pfizer (PFE) reported 1st quarter earnings that were largely viewed as a mixed bag. But far more interesting to me, was this 8K that Pfizer filed on Monday. In the filing, the company notes that Dr. Corey S. Goodman, who ran Pfizer’s Biotherapeutics and Bioinnovation Center in South San Francisco, plans to step down at the...

  • Welcome, Wyeth, to Pfizer's Biotech Federation

    The In Vivo Blog - 299 days 16 hours 8 minutes ago

    This was, more or less, what Corey Goodman, president of Pfizer's 18-month old Biotherapeutics and Bioinnovation Center (BBC), had to say yesterday about his company's latest purchase. In fact it was more than a welcome, it was a positive bear-hug: "We expect that some of Wyeth's biologics and biotech-like units will have the kind of culture and...

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here